Kenjiro Namikawa
YOU?
Author Swipe
View article: Treatment Outcomes of Surgery and <scp>ICI</scp> Therapy in 52 Patients With Esophageal Melanoma: A Retrospective Single‐Center Cohort Study
Treatment Outcomes of Surgery and <span>ICI</span> Therapy in 52 Patients With Esophageal Melanoma: A Retrospective Single‐Center Cohort Study Open
Primary malignant melanoma of the esophagus (PMME) accounts for only 0.5% of all melanomas but is associated with the shortest interval to disease progression and the highest metastasis rate. The optimal treatment for PMME remains elusive.…
View article: Response to Crizotinib in <scp>ROS1</scp> Fusion‐Positive Metastatic Angiosarcoma of the Scalp: A Case Report
Response to Crizotinib in <span>ROS1</span> Fusion‐Positive Metastatic Angiosarcoma of the Scalp: A Case Report Open
View article: Pembrolizumab Plus Lenvatinib in the Treatment of Unresectable Cutaneous Angiosarcoma: A study protocol of Multicenter, Open-label Phase II Study (NCCH2213, PLAS)
Pembrolizumab Plus Lenvatinib in the Treatment of Unresectable Cutaneous Angiosarcoma: A study protocol of Multicenter, Open-label Phase II Study (NCCH2213, PLAS) Open
Background: Cutaneous angiosarcoma (cAS) is a rare, aggressive malignancy with poor prognosis. The most common age for cAS is 79–85 years, and the number of cAS patients is increasing owing to the aging population. Standard treatment for c…
View article: Correction to: Melanoma skin cancer statistics derived from 7442 Japanese patients: Japanese melanoma study
Correction to: Melanoma skin cancer statistics derived from 7442 Japanese patients: Japanese melanoma study Open
View article: Japanese Dermatological Association Guidelines: Clinical Questions of Guidelines for Melanoma 2025
Japanese Dermatological Association Guidelines: Clinical Questions of Guidelines for Melanoma 2025 Open
Advancements in melanoma management have underscored the need for periodic guideline updates every few years to reflect current clinical practices. Previous versions of melanoma clinical practice guidelines in Japan have primarily aimed to…
View article: Phase II trial dedicated to non-selected, pretreated cutaneous angiosarcoma: Efficacy of nivolumab (AngioCheck Study)
Phase II trial dedicated to non-selected, pretreated cutaneous angiosarcoma: Efficacy of nivolumab (AngioCheck Study) Open
Nivolumab monotherapy did not achieve the predefined response rate in this cohort of pretreated cutaneous angiosarcoma patients. No correlation between TMB-high status and objective response was identified. Further investigations are neede…
View article: Melanoma skin cancer statistics derived from 7442 Japanese patients: Japanese melanoma study
Melanoma skin cancer statistics derived from 7442 Japanese patients: Japanese melanoma study Open
Background Malignant melanoma (MM) is a rare but aggressive cutaneous cancer, accounting for only 2% of skin cancers in Japan but nearly half of skin cancer-related deaths. While the global incidence of MM is rising, its epidemiology varie…
View article: Benefits of Combining Circulating Tumor DNA With Tissue and Longitudinal Circulating Tumor DNA Genotyping in Advanced Solid Tumors: SCRUM-Japan MONSTAR-SCREEN-1 Study
Benefits of Combining Circulating Tumor DNA With Tissue and Longitudinal Circulating Tumor DNA Genotyping in Advanced Solid Tumors: SCRUM-Japan MONSTAR-SCREEN-1 Study Open
PURPOSE The utility of capturing heterogeneity by circulating tumor DNA (ctDNA) genotyping combined with tissue analysis or applying it in a sequential manner remains uncertain. METHODS We assessed the clinical value of ctDNA genotyping us…
View article: Japan society of clinical oncology position paper on appropriate clinical use of molecular residual disease (MRD) testing
Japan society of clinical oncology position paper on appropriate clinical use of molecular residual disease (MRD) testing Open
View article: Clinical characteristics and treatments of Merkel cell carcinoma in Japan: A multi-center retrospective study
Clinical characteristics and treatments of Merkel cell carcinoma in Japan: A multi-center retrospective study Open
View article: Clinical Characteristics and Treatments of Merkel Cell Carcinoma in Japan: A Multi-Center Retrospective Study
Clinical Characteristics and Treatments of Merkel Cell Carcinoma in Japan: A Multi-Center Retrospective Study Open
View article: A retrospective observational study of patients with melanoma prescribed combined BRAF and MEK inhibitors in a real‐world treatment setting in Japan
A retrospective observational study of patients with melanoma prescribed combined BRAF and MEK inhibitors in a real‐world treatment setting in Japan Open
Objective This study aimed to describe patients with melanoma initiating treatments with dabrafenib plus trametinib (Dab + Tram) or encorafenib plus binimetinib (Enco + Bini) in a real‐world setting in Japan. Methods Data were extracted fr…
View article: Boron neutron capture therapy for cutaneous angiosarcoma and malignant melanoma: First in-human phase I clinical trial
Boron neutron capture therapy for cutaneous angiosarcoma and malignant melanoma: First in-human phase I clinical trial Open
BNCT with a dose of 18 Gy-Eq is a feasible treatment option, demonstrating a favorable safety profile and a high response rate in patients with primary or recurrent angiosarcoma or malignant melanoma of the skin.
View article: The impact of rare cancer and early-line treatments on the benefit of comprehensive genome profiling-based precision oncology
The impact of rare cancer and early-line treatments on the benefit of comprehensive genome profiling-based precision oncology Open
View article: Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study Open
The authors added detailed treatment data which may be valuable information for readers to their study "Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive sur…
View article: Long‐term survival with systemic therapy in the last decade: Can melanoma be cured?
Long‐term survival with systemic therapy in the last decade: Can melanoma be cured? Open
Immune checkpoint inhibitors have been shown to prolong survival of patients with several types of cancer, and the finding was first established in melanoma. Previously, systemic therapy for advanced melanoma aimed only at tumor control an…
View article: Benefit, recurrence pattern, and toxicity to adjuvant anti-PD-1 monotherapy varies by ethnicity and melanoma subtype: An international multicenter cohort study
Benefit, recurrence pattern, and toxicity to adjuvant anti-PD-1 monotherapy varies by ethnicity and melanoma subtype: An international multicenter cohort study Open
View article: A single‐center retrospective analysis of prognoses in patients with melanoma brain metastases and effectiveness of treatment in Japan
A single‐center retrospective analysis of prognoses in patients with melanoma brain metastases and effectiveness of treatment in Japan Open
Background Melanoma brain metastasis (MBM) has a poor prognosis, although recent treatments, including immune checkpoint inhibitors and targeted therapy, have improved the prognosis. However, these systemic therapies have been reported to …
View article: Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study Open
View article: A retrospective study of sentinel lymph node biopsy for skin cancer in Japan: Comparison with breast cancer and evaluation of factors related to its use
A retrospective study of sentinel lymph node biopsy for skin cancer in Japan: Comparison with breast cancer and evaluation of factors related to its use Open
Background Sentinel lymph node biopsy (SLNB) underuse has been reported for skin cancers; however, actual performance rates have not been compared. The objective of this study was to investigate the SLNB performance rate in skin cancers co…
View article: Acral cutaneous malignant melanoma treated with linear accelerator-based boron neutron capture therapy system: a case report of first patient
Acral cutaneous malignant melanoma treated with linear accelerator-based boron neutron capture therapy system: a case report of first patient Open
This study reports the first patient treatment for cutaneous malignant melanoma using a linear accelerator-based boron neutron capture therapy (BNCT) system. A single-center open-label phase I clinical trial had been conducted using the sy…
View article: Strategic Approach to Heterogeneity Analysis of Cutaneous Adnexal Carcinomas Using Computational Pathology and Genomics
Strategic Approach to Heterogeneity Analysis of Cutaneous Adnexal Carcinomas Using Computational Pathology and Genomics Open
View article: Systemic therapy for Asian patients with advanced <scp>BRAF V600</scp>‐mutant melanoma in a real‐world setting: A multi‐center retrospective study in Japan (<scp>B‐CHECK‐RWD</scp> study)
Systemic therapy for Asian patients with advanced <span>BRAF V600</span>‐mutant melanoma in a real‐world setting: A multi‐center retrospective study in Japan (<span>B‐CHECK‐RWD</span> study) Open
Background Anti‐PD‐1‐based immunotherapy is considered a preferred first‐line treatment for advanced BRAF V600‐mutant melanoma. However, a recent international multi‐center study suggested that the efficacy of immunotherapy is poorer in As…
View article: Efficacy of salvage therapies for advanced acral melanoma after anti-PD-1 monotherapy failure: a multicenter retrospective study of 108 Japanese patients
Efficacy of salvage therapies for advanced acral melanoma after anti-PD-1 monotherapy failure: a multicenter retrospective study of 108 Japanese patients Open
Background Anti-programmed cell death protein 1 (PD-1) monotherapy is one of the standard systemic therapies for advanced melanoma; however, the efficacy of salvage systemic therapies after PD-1 monotherapy failure (PD-1 MF), particularly …
View article: Treatment of high tumor mutation burden metastatic extramammary Paget disease with an anti–<scp>PD</scp>‐1 antibody
Treatment of high tumor mutation burden metastatic extramammary Paget disease with an anti–<span>PD</span>‐1 antibody Open
Table S1. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the…
View article: Congenital dermatofibrosarcoma protuberans with PDGFB gene rearrangement detected using fluorescence in situ hybridization
Congenital dermatofibrosarcoma protuberans with PDGFB gene rearrangement detected using fluorescence in situ hybridization Open
View article: Prognostic factors in cutaneous apocrine carcinoma: A single-institution retrospective study of 32 patients
Prognostic factors in cutaneous apocrine carcinoma: A single-institution retrospective study of 32 patients Open
Background Cutaneous apocrine carcinoma (CAC) is a rare adnexal carcinoma. Limited data exists on the demographics and overall survival (OS) of patients with CAC; thus, there is no consensus on surgical management. This study aimed to exam…
View article: Epidemiology of skin cancer based on Japan's National Cancer Registry 2016–2017
Epidemiology of skin cancer based on Japan's National Cancer Registry 2016–2017 Open
Skin cancer is most frequently diagnosed in the White population. However, its subtypes and epidemiology in Japan are understudied. We aimed to elucidate skin cancer incidence in Japan based on the National Cancer Registry, a new nationwid…
View article: 1256 The Effects of ALDH 2 polymorphisms on pathogenesis and treatment response in malignant melanoma
1256 The Effects of ALDH 2 polymorphisms on pathogenesis and treatment response in malignant melanoma Open
View article: Data from Correlation of Tumor Burden in Sentinel Lymph Nodes with Tumor Burden in Nonsentinel Lymph Nodes and Survival in Cutaneous Melanoma
Data from Correlation of Tumor Burden in Sentinel Lymph Nodes with Tumor Burden in Nonsentinel Lymph Nodes and Survival in Cutaneous Melanoma Open
Purpose:In patients with cutaneous melanoma, metastasis in a nonsentinel lymph node (non-SLN) is a strong independent adverse prognostic factor. However, patients with a tumor-involved SLN no longer routinely undergo completion lymph node …